Graft-versus-Host Disease: State of the Science

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 1 SUPPL., 2013, Pages

  Alousi, Amin M ^a   Bolaños Meade, Javier ^b   Lee, Stephanie J ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; BUSULFAN; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; FLUDARABINE; MARAVIROC; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PREDNISONE; RAPAMYCIN; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL EVALUATION; CLINICAL RESEARCH; DRUG WITHDRAWAL; EX VIVO STUDY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; LONGITUDINAL STUDY; MYELOABLATIVE CONDITIONING; SCIENCE; T CELL DEPLETION; TREATMENT RESPONSE;

ACUTE DISEASE; ANIMALS; BIOMEDICAL RESEARCH; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HUMANS;

EID: 84871903785     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.10.028     Document Type: Article

References (36)

1. Cutler C., Stevenson K., Kim H.T., et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 2008, 112:4425-4431.
2. + selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol 2012, 30:3194-3201.
3. Bayraktar U.D., De Lima M., Rima S.M., et al. Ex vivo T celledepleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission: a comparison of outcomes in two institutions. Blood (ASH Annual Meeting Abstracts) Nov 2011 2013, 118.
4. Finke J., Bethge W.A., Schmoor C., et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009, 10:855-864.
5. Soiffer R.J., Lerademacher J., Ho V., et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011, 117:6963-6970.
6. Parmar S., Andersson B.S., Couriel D., et al. Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. J Clin Oncol 2011, 29:294-302.
7. Luznik L., Bolanos-Meade J., Zahurak M., et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010, 115:3224-3230.
8. Alousi A, Saliba R, Chen J, et al. A matched controlled analysis of posttransplant cyclophosphamide (Cy) versus tacrolimus and mini-dose methotrexate in matched sibling and unrelated donor transplant recipients receiving reduced-intensity conditioning: post-transplant Cy is associated with higher rates of acute GVHD. Atlanta, Georgia: The University of Texas M D Anderson Cancer Center. Blood (ASH Annual Meeting Abstracts) Nov 2012; 120(21): 4200.
9. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.
10. Koreth J., Stevenson K.E., Kim H.T., et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol 2012, 30:3202-3208.
11. Reshef R., Luger S.M., Hexner E.O., et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 2012, 367:135-145.
12. Martin P.J., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990, 76:1464-1472.
13. Martin P.J., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991, 77:1821-1828.
14. Weisdorf D., Haake R., Blazar B., et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990, 75:1024-1030.
15. Cragg L., Blazar B.R., Defor T., et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 2000, 6:441-447.
16. Lee S.J., Zahrieh D., Agura E., et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004, 104:1559-1564.
17. Alousi A.M., Weisdorf D.J., Logan B.R., et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009, 114:511-517.
18. Korn E.L., Freidlin B., Abrams J.S., et al. Design issues in randomized phase II/III trials. J Clin Oncol 2012, 30:667-671.
19. Jacobson P.A., Huang J., Wu J., et al. Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant 2010, 16:421-429.
20. Levine J.E., Logan B., Wu J., et al. Graft-versus-host disease treatment: predictors of survival. Biol Blood Marrow Transplant 2010, 16:1693-1699.
21. Levine J.E., Logan B.R., Wu J., et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 2012, 119:3854-3860.
22. Paczesny S., Krijanovski O.I., Braun T.M., et al. A biomarker panel for acute graft-versus-host disease. Blood 2009, 113:273-278.
23. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, I: Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
24. Shulman H.M., Kleiner D., Lee S.J., et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, II: Pathology Working Group report. Biol Blood Marrow Transplant 2006, 12:31-47.
25. Schultz K.R., Miklos D.B., Fowler D., et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, III: Biomarker Working Group report. Biol Blood Marrow Transplant 2006, 12:126-137.
26. Pavletic S.Z., Martin P., Lee S.J., et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, IV: Response Criteria Working Group report. Biol Blood Marrow Transplant 2006, 12:252-266.
27. Couriel D., Carpenter P.A., Cutler C., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, V: Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006, 12:375-396.
28. Martin P.J., Weisdorf D., Przepiorka D., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, VI: Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant 2006, 12:491-505.
29. Arai S., Jagasia M., Storer B., et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood 2011, 118:4242-4249.
30. Pidala J., Kurland B., Chai X., et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood 2011, 117:4651-4657.
31. Pidala J., Kurland B.F., Chai X., et al. Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium. Haematologica 2011, 96:1528-1535.
32. Inamoto Y., Chai X., Kurland B.F., et al. Validation of measurement scales in ocular graft-versus-host disease. Ophthalmology 2012, 119:487-493.
33. Jacobsohn D., Lee S.J., Kurland B., et al. Change in NIH skin score 0-3 correlates with provider- and patient-reported skin changes and overall survival: results from the Chronic GVHD Consortium. Blood 2012, 120:2545-2552.
34. Inamoto Y., Martin P.J., Chai X., et al. The clinical benefit of response in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012, 18:1517-1524.
35. Palmer J.M., Lee S.J., Chai X., et al. Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012, 18(11):1649-1655.
36. Rationale and design of the Chronic GVHD Cohort Study: improving outcomes assessment in chronic GVHD. Biol Blood Marrow Transplant 2011, 17:1114-1120. Chronic GVHD Consortium.